Breakthrough Genetic Discovery Helps Dermatologists Prescribe Effective Treatment For Female Hair Loss

DermaGenoma Launches HairDX Genetic Test for Female Androgen Sensitivity

BOSTON--()--Genetics research and a clinical study are today bringing significant news to women experiencing hair loss. A new breakthrough test can now help doctors determine if a woman is likely to benefit from anti-androgen therapies.

Genetic dermatology research and development innovator DermaGenoma, Inc. today announces the HairDX Genetic Test for Female Androgen Sensitivity. The test offers a new genetic screening for women suffering from or at risk of androgenetic alopecia (AGA), and is making its debut to physicians at the International Society of Hair Restoration Surgery’s 18th Annual Scientific Meeting in Boston.

The HairDX Genetic Test for Female Androgen Sensitivity (to be available through dermatologists at a suggested price of $399) examines genetic and epigenetic (genetic control mechanism) variations in a woman’s androgen receptor gene. This analysis will assess her androgen sensitivity to determine if her hair loss has an androgenic origin.

Androgens are the male sex hormones testosterone and dihydrotestosterone that bind and activate the androgen receptor (AR). The activated AR influences normal cellular functions in both men and women. Differences in androgen sensitivity due to genetic variations in the AR gene have been associated with hair loss and response to anti-androgen therapy.

A DermaGenoma clinical study of female AGA patients has shown that finasteride* has a better therapeutic effect on individuals with a high androgen sensitivity.

“Patients with certain genetic and epigenetic variations have an increase in androgen receptor activity and therefore high androgen sensitivity,” says Dr. Sharon Keene, Chief Medical Officer for DermaGenoma, Inc.

Knowing the woman’s androgen sensitivity will help her doctor determine if her hair loss has an androgenic basis. Patients with high androgen sensitivity could benefit from anti-androgen therapies. Understanding the origin of the hair loss will help the physician select the most effective treatment.

“This revolutionizes potential dermatologic treatments for female hair loss,” says Andy Goren, CEO of DermaGenoma, Inc.

The first practices carrying HairDX Genetic Test for Female Androgen Sensitivity are Bosley Medical, with 23 surgical offices and more than 80 office locations in the U.S., Canada and Mexico. The test is also available through Dr. Janet Roberts of Portland, OR, Bauman Medical Group of Boca Raton, FL, and Ziering Medical with offices in Beverly Hills and Newport Beach, CA and Las Vegas, NV.

"This test addresses a long standing clinical need in the treatment of women with hair loss; the ability to identify those patients who will benefit from a specific type of hormonal therapy," says Dr. Kenneth Washenik, Medical Director of Bosley and the Executive Vice President of Scientific and Medical Development of the Aderans Research Institute. "This test adds much needed specificity to our ability to evaluate androgenetic alopecia in women suffering from hair loss."

*At this time certain anti-androgen therapies such as finasteride are not approved by the U.S. FDA for use in women. This test does not endorse or encourage the use of off-label prescription medication.

About DermaGenoma, Inc.

Headquartered in Irvine, CA, DermaGenoma, Inc. is a genetic dermatology company founded by leading researchers and specialists in genetics and dermatology. The company is dedicated to the research and development of new diagnostics and prescription-based therapies for skin conditions tailored to an individual’s genetic makeup.

DermaGenoma genetic tests are available through physicians’ offices nationwide, and are administered using a simple cheek swab.

Follow DermaGenoma on Twitter: @DermaGenomaInc and on Facebook.

Contacts

DermaGenoma, Inc.
Jon Boroshok, 978-502-1055
Public Relations
jonb@DermaGenoma.com
Twitter: @DermaGenomaInc

Release Summary

A new breakthrough test can now help doctors determine if a woman is likely to benefit from anti-androgen therapies

Contacts

DermaGenoma, Inc.
Jon Boroshok, 978-502-1055
Public Relations
jonb@DermaGenoma.com
Twitter: @DermaGenomaInc